

Final Draft Agenda
45th meeting of the Committee for Socio-economic Analysis

26-28 November 2019
and
3-5 December 2019

ECHA Conference Centre (Annankatu 18, Helsinki)

Tuesday 26 November starts at 14.00
Thursday 28 November breaks at 17.00
Tuesday 3 December resumes at 14.00
Thursday 5 December ends at 17.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

SEAC/A/45/2019
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on SEAC-44 action points, written procedures and update on other ECHA bodies

For information

Item 5 – Restrictions

5.1 General restriction issues

- a) Report from the Restrictions Efficiency Task Force

For information

5.2 Restriction Annex XV dossiers

a) Opinion development

- 1) Calcium cyanamide in fertilisers – first draft opinion
- 2) Skin sensitisers in textile – second draft opinion
- 3) Perfluorohexane-1-sulphonic acid, its salts and related substances – second draft opinion
- 4) Microplastics – third draft opinion
For discussion
- 5) Siloxanes (D4, D5 and D6) – third draft opinion
- 6) Formaldehyde – third draft opinion
- 7) Five cobalt salts – fourth draft opinion
For discussion and agreement
- 8) *N,N*-dimethylformamide – draft final opinion
For discussion and adoption

5.3 Appointment of (co-)rapporteurs for restriction dossiers

SEAC/45/2019/01
(restricted document)
For agreement

Item 6 – Authorisation

6.1 General authorisation issues

- #### a) Update on incoming/future applications

For information

6.2 Authorisation applications

- #### a) Discussion on key issues

- 1) 19 applications for authorisation from August 2019 submission window (OPE/NPE)

For discussion

- #### b) Agreement on draft opinion

- 1) 146_CT_TataSteel (1 use)

- 2) 147_CTPht_AO_Bilbaina (1 use)
- 3) 149_CTPht_Nalon (1 use)
- 4) 150_CTPht_AO_Koppers (1 use)
- 5) 151_CTPht_AO_Rutgers (1 use)
- 6) 152_CTPht_AO_RainCarbon (1 use)
- 7) 155_OPE_Siemens_2 (5 uses)
- 8) 157_OPE_Kedrion (1 use)
- 9) 158_OPE_Sanofi (1 use)
- 10) 159_OPE_Merck (1 use)
- 11) 161_OPE_Swords (1 use)
- 12) 166_OPE_Ompi (1 use)
- 13) 167_OPE_Roche (1 use)
- 14) 168_OPE_Vetter (1 use)
- 15) 169_OPE_Nordisk (1 use)
- 16) 171_OPE_Wallac (2 uses)
- 17) 173_OPE_Sobi (1 use)
- 18) 176_OPE_Abbott_1 (5 uses)
- 19) 177_OPE_Abbott_2 (1 use)
- 20) 178_OPE_Janssen (1 use)
- 21) 179_OPE_Octapharma (2 uses)
- 22) 181_OPE_NPE_Roche (3 uses)
- 23) 183_NPE_GEHC_Bio-Sciences (1 use)

For discussion and agreement

c) Status update

- 1) 148_CTPht_DEZA (1 use)
- 2) 153_CTPht_Bilbaina (1 use)

For information

6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)

*SEAC/45/2019/02
(restricted room document)
For agreement*

Item 7 – AOB

a) Update of the work plan

For information

Item 8 – Action points and main conclusions of SEAC-45

Table with Conclusions and Action points from SEAC-45

For adoption